IPP Bureau
Arvinas and Pfizer announce updated clinical data from Phase 1b Trial of Vepdegestrant in combination with Palbociclib
By IPP Bureau - May 18, 2024
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Glenmark launches next phase of ‘India First Heart First’ campaign
By IPP Bureau - May 17, 2024
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Takeda appoints Annapurna Das as the General Manager, India Operations
By IPP Bureau - May 17, 2024
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
By IPP Bureau - May 17, 2024
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Elinzanetant significantly reduces frequency and severity of hot flashes associated with menopause
By IPP Bureau - May 17, 2024
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
By IPP Bureau - May 17, 2024
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Cipla invests additional Rs. 26 crore in Achira
By IPP Bureau - May 16, 2024
Achira is engaged in development and commercialization of PoC medical test kits in India
Granules India posts Q4 FY24 consolidated PAT at Rs. 129.64 Cr
By IPP Bureau - May 16, 2024
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr
By IPP Bureau - May 16, 2024
The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024
Bayer starts Phase I study with novel targeted radionuclide therapy in advanced metastatic prostate cancer
By IPP Bureau - May 16, 2024
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr
By IPP Bureau - May 15, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
